Schedules of Controlled Substances: Rescheduling of Marijuana; Withdrawal
The DEA has withdrawn its proposed rule to reschedule marijuana from Schedule I to Schedule III, maintaining its current status. This reversal impacts pharmaceutical manufacturers involved with marijuana-derived or synthetic cannabinoid products, as well as those relying on the proposed change for research or commercial purposes.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Pharmaceutical manufacturers handling marijuana or cannabinoid-based drugs, including API manufacturers, generic/ANDA makers, and compounding outsourcing facilities (503B). should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; no grace period as the withdrawal is effective upon publication.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The proposed rescheduling of marijuana to Schedule III has been withdrawn, meaning marijuana remains a Schedule I controlled substance with strict research and manufacturing restrictions.
Who it affects
Pharmaceutical manufacturers handling marijuana or cannabinoid-based drugs, including API manufacturers, generic/ANDA makers, and compounding outsourcing facilities (503B).
What you must do
Review and adjust compliance programs, research protocols, and supply chain agreements to align with Schedule I requirements; cease any activities contingent on rescheduling.
Deadline
Immediately; no grace period as the withdrawal is effective upon publication.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness